加味五苓散联合康柏西普治疗肝郁脾虚型糖尿病性黄斑水肿的临床研究

周娜; 姜凤; 刘瑞宝

doi:10.16766/j.cnki.issn.1674-4152.003729

加味五苓散联合康柏西普治疗肝郁脾虚型糖尿病性黄斑水肿的临床研究

doi: 10.16766/j.cnki.issn.1674-4152.003729

周娜^{1, 2, ,},
姜凤³,
刘瑞宝¹

1.
河南中医药大学第一附属医院眼科，河南郑州 471000
2.
河南中医药大学第一临床医学院，河南郑州 471000
3.
重庆市合川区中医院眼科, 四川重庆 401520

基金项目:

河南省中医药科学研究专项课题 2022ZY1010

详细信息

通讯作者:
周娜，E-mail：Zhou5339@163.com

中图分类号: R587.2
计量
- 文章访问数: 31
- HTML全文浏览量: 22
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2024-03-19
- 网络出版日期: 2024-12-28

The clinical study of modified Wuling Powder Combined with conbercept in the treatment of diabetic macular edema of liver depression and spleen deficiency

ZHOU Na^{1, 2
, ,},
JIANG Feng³,
LIU Ruibao¹

1.
Ophthalmology Department, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 471000, China

摘要

摘要: 目的研究加味五苓散联合康柏西普治疗肝郁脾虚型糖尿病性黄斑水肿(DME)的临床效果。方法选取2020年12月—2023年5月在河南中医药大学第一附属医院眼科治疗的肝郁脾虚型DME患者86例(86眼)，以随机数字表法分为观察组(43例，采用加味五苓散联合康柏西普治疗)及对照组(43例，采用康柏西普治疗)，比较2组患者的临床疗效、中医证候积分、视力水平、黄斑厚度、血清因子水平及不良反应发生率，运用SPSS 22.0统计学软件进行分析。结果治疗3个月后，观察组治疗总有效率(95.35%，41/43)高于对照组(81.40%，35/43，χ²=4.074，P=0.044)；2组患者中医证候积分、视力水平、黄斑厚度、白细胞介素-6及血管内皮生长因子均降低，且观察组较对照组低(P＜0.05)；2组患者一氧化氮合酶水平均升高，且观察组较对照组高(P＜0.05)；2组患者不良反应总发生率分别为9.30%(4/43)、11.63%(5/43)，差异无统计学意义(P＞0.05)。结论加味五苓散联合康柏西普治疗肝郁脾虚型DME具有较好的疗效，可显著改善患者临床症状、血管内皮功能及视力，降低黄斑厚度，减轻炎症反应，安全性高。
- 加味五苓散 /
- 康柏西普 /
- 肝郁脾虚型糖尿病性黄斑水肿
Abstract: Objective To examine the clinical impact of a modified Wuling Powder combined with Conbercept on diabetic macular edema (DME) in patients with liver depression and spleen deficiency. Methods The study subjects were 86 patients (86 eyes) with DME of liver depression and spleen deficiency treated in the Department of Ophthalmology at the First Affiliated Hospital of Henan University of Chinese Medicine between December 2020 and May 2023. The subjects were randomly assigned to either the observation group (n=43, modified Wuling Powder combined with Conbercept) and the control group (n=43, Conbercept) using a random number table method. A comparison was made of the clinical efficacy, traditional Chinese medicine (TCM) syndrome score, visual acuity level, macular thickness, serum factor level and incidence of adverse reactions in the two groups. The statistical analysis was conducted using SPSS 22.0 software. Results The observation group exhibited higher total effective rate [95.35% (43/43) vs. 81.40% (35/43)] 3 months following treatment (χ²=4.074, P=0.044). The TCM syndrome scores, visual acuity levels, macular thickness indexes, interleukin-6 and vascular endothelial growth factor levels in both groups decreased, with the observation group exhibiting lower levels (P < 0.05), conversely, the nitric oxide synthase levels increased in both groups, with the observation group demonstrating higher levels (P < 0.05). With regard to adverse reactions, no statistically significant difference was observed between the two groups [9.30% (4/43) vs. 11.63% (5/43), P>0.05]. Conclusion The combination of modified Wuling Powder with Conbercept has been demonstrated to be an effective treatment for DME caused by hepatic depression and splenic deficiency. It has the capacity to significantly improve the clinical symptoms of patients, enhance their visual acuity, reduce macular thickness, alleviate inflammatory response, and improve vascular endothelial function. Furthermore, it has been shown to be a safe treatment option.
- Modified Wuling Powder /
- Conbercept /
- Diabetic macular edema of liver depression and spleen deficiency

HTML全文

表 1 2组肝郁脾虚型DME患者临床总有效率比较[例(%)]

Table 1. Comparison of clinical efficacy of DME patients with liver-stagnation and spleen-deficiency between the two groups[cases (%)]

组别	例数	显效	有效	无效	总有效
观察组	43	26(60.47)	15(34.88)	2(4.65)	41(95.35)
对照组	43	12(27.91)	23(53.49)	8(18.60)	35(81.40)
统计量			3.210^a		4.074^b
P值			0.001		0.044
注：^a为Z值，^b为χ²值。

下载: 导出CSV

表 2 2组肝郁脾虚型DME患者中医证候积分比较(x±s，分)

Table 2. Comparison of TCM syndrome scores between the two groups of liver-stagnation and spleen-deficiency DME patients (x±s, points)

组别	例数	视物昏花		眼部干涩		气短懒言		面色晦暗		五心烦热		乏力
组别	例数	治疗前	治疗3个月后	治疗前	治疗3个月后	治疗前	治疗3个月后	治疗前	治疗3个月后	治疗前	治疗3个月后	治疗前	治疗3个月后
观察组	43	4.35±0.78	1.69±0.47	4.62±0.51	2.01±0.54	4.49±0.62	1.76±0.52	2.24±0.41	1.08±0.31	2.16±0.48	0.97±0.29	2.07±0.54	0.83±0.24
对照组	43	4.11±0.83	1.98±0.43	4.49±0.63	2.45±0.48	4.34±0.66	2.08±0.49	2.09±0.43	1.26±0.28	2.04±0.53	1.13±0.27	2.01±0.56	0.99±0.22
统计量		1.382^a	2.985^b	1.052^a	3.993^b	1.086^a	2.937^b	1.656^a	2.826^b	1.100^a	2.648^b	0.506^a	3.223^b
P值		0.171	0.004	0.296	＜0.001	0.281	0.004	0.102	0.006	0.274	0.010	0.614	0.002
注：^a为t值，^b为F值。

下载: 导出CSV

表 3 2组肝郁脾虚型DME患者视力水平、黄斑厚度比较(x±s)

Table 3. Comparison of visual acuity level and macular thickness between the two groups of liver-stagnation and spleen-deficiency DME patients(x±s)

组别	例数	最佳矫正视力(LogMAR)		黄斑中心凹下脉络膜厚度(μm)		黄斑中心凹下视网膜厚度(μm)
组别	例数	治疗前	治疗3个月后	治疗前	治疗3个月后	治疗前	治疗3个月后
观察组	43	0.84±0.21	0.43±0.13	194.69±9.64	156.34±3.52	487.38±12.04	303.42±5.29
对照组	43	0.79±0.23	0.52±0.11	192.83±9.97	158.73±3.28	485.89±13.12	308.15±5.72
统计量		1.053^a	3.466^b	0.879^a	3.257^b	0.549^a	3.981^b
P值		0.296	0.001	0.382	0.002	0.585	＜0.001
注：^a为t值，^b为F值。

下载: 导出CSV

表 4 2组肝郁脾虚型DME患者血清因子水平比较(x±s)

Table 4. Comparison of serum factor levels in liver depression and spleen deficiency DME patients between the two groups(x±s)

组别	例数	IL-6(ng/L)		VEGF(mg/L)		NOS(IU/mL)
组别	例数	治疗前	治疗3个月后	治疗前	治疗3个月后	治疗前	治疗3个月后
观察组	43	35.46±2.58	18.33±2.26	218.43±9.64	115.18±3.95	46.71±3.48	89.45±2.73
对照组	43	34.67±2.72	20.28±2.13	216.79±9.78	118.41±3.63	45.56±3.59	87.16±2.88
统计量		1.382^a	4.117^b	0.783^a	3.948^b	1.508^a	3.784^b
P值		0.171	＜0.001	0.436	＜0.001	0.135	＜0.001
注：^a为t值，^b为F值。

下载: 导出CSV

表 5 2组肝郁脾虚型DME患者不良反应发生率比较[例(%)]

Table 5. Incidence of adverse reactions in 2 groups[cases (%)]

组别	例数	结膜出血	干眼症	玻璃体出血	高眼压	总发生
观察组	43	0	2(4.65)	1(2.33)	1(2.33)	4(9.30)
对照组	43	2(4.65)	0	1(2.33)	2(4.65)	5(11.63)
注：2组不良反应总发生率比较，χ²=0.124，P=0.725。

下载: 导出CSV

参考文献(22)

[1]	SOROUR O A, LEVINE E S, BAUMAL C R, et al. Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods[J]. Surv Ophthalmol, 2023, 68(2): 147-174. doi: 10.1016/j.survophthal.2022.11.008
[2]	SHIMURA M, KITANO S, OGATA N, et al. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial[J]. Jpn J Ophthalmol, 2023, 67(3): 264-279. doi: 10.1007/s10384-023-00979-8
[3]	TAKAMURA Y, YAMADA Y, MORIOKA M, et al. Turnover of microaneurysms after intravitreal injections of faricimab for diabetic macular edema[J]. Invest Ophthalmol Vis Sci, 2023, 64(13): 31. doi: 10.1167/iovs.64.13.31
[4]	EVERETT L A, PAULUS Y M. Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema[J]. Curr Diab Rep, 2021, 21(9): 35. doi: 10.1007/s11892-021-01403-6
[5]	马素红, 储俐, 左玉霞. 自拟化瘀明目汤联合针刺治疗糖尿病性黄斑水肿的临床观察[J]. 中国中医急症, 2019, 28(8): 1471-1474. MA S H, CHU L, ZUO Y X. Clinical observation of self-prepared Huayu Mingmu Decoction combined with acupuncture in the treatment of diabetic macular edema[J]. Journal of Emergency in Traditional Chinese Medicine, 2019, 28(8): 1471-1474.
[6]	刘淑萍. 桃红四物汤联合激光对糖尿病性黄斑水肿患者血脂及血清一氧化碳合酶血管内皮生长因子白细胞介素-6的影响[J]. 中国药物与临床, 2021, 21(24): 4046-4048. LIU S P. Effect of Peach Hong Siwu Decoction combined with laser on blood lipid and serum carbon monoxide synthase vascular endothelial growth factor interleukin-6 in patients with diabetic macular edema[J]. Chinese Medicine and Clinic, 2021, 21(24): 4046-4048.
[7]	李萱, 谢立科, 郝晓凤, 等. 五苓散在眼科病症黄斑水肿临证中的应用[J]. 广州中医药大学学报, 2022, 39(5): 1184-1190. LI X, XIE L K, HAO X F, et al. Practice of Wuling Powder for the Treatment of Macular Edema[J]. Journal of Guangzhou University of Traditional Chinese Medicine, 2022, 39(5): 1184-1190.
[8]	李筱荣, 黎晓新, 惠延年. 糖尿病眼病[M]. 北京: 人民卫生出版社, 2010: 67-106. LI X R, LI X X, HUI Y N. Diabetic eye disease[M]. Beijing: People ' s Medical Publishing House, 2010: 67-106.
[9]	国家技术监督局. 中华人民共和国国家标准中医临床诊疗术语(证候部分)[S]. 北京: 国家技术监督局, 1997. State Bureau of Technical Supervision. People ' s Republic of China National Standard TCM clinical diagnosis and treatment terms (Syndrome part)[S]. Beijing: State Bureau of Technical Supervision, 1997.
[10]	国家中医药管理局. 中医病证诊断疗效标准1994[S]. 南京: 南京大学出版社, 1994: 88-89. National Administration of Traditional Chinese Medicine (NATCM). Chinese medicine disease diagnosis and curative effect standard 1994[S]. Nanjing: Nanjing University Press, 1994: 88-89.
[11]	国家食品药品监督管理总局. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 312. State Food and Drug Administration. Guiding principles for clinical research of new Chinese medicine[M]. Beijing: China Medical Science and Technology Press, 2002: 312.
[12]	张虹, 周云云, 李雨薇, 等. 雷晓琴从痰瘀论治糖尿病黄斑水肿经验[J]. 四川中医, 2019, 37(9): 8-9. ZHANG H, ZHOU Y Y, LI Y W, et al. LEI Xiaoqin ' s Experience Who Treated Diabetic Macular Edema from Phlegm and Blood Stasis[J]. Sichuan Traditional Chinese Medicine, 2019, 37(9): 8-9.
[13]	李雨薇, 周云云, 张英英, 等. 雷晓琴从水血互因论治糖尿病黄斑水肿经验[J]. 四川中医, 2019, 37(2): 3-5. LI Y W, ZHOU Y Y, ZHANG Y Y, et al. LEI Xiaoqin ' s Experience in Treating Diabetic Macular Edema from Water and Blood Factors[J]. Sichuan Traditional Chinese Medicine, 2019, 37(2): 3-5.
[14]	赵鑫, 胥朵, 李少海, 等. 桃红四物汤合六味地黄汤联合雷珠单抗玻璃体内注射治疗糖尿病性黄斑水肿疗效观察[J]. 四川中医, 2022, 40(2): 130-133. ZHAO X, XU D, LI S H, et al. Therapeutic Effect of Taohong Siwu Decoction and Liuwei Dihuang Decoction Combined with Intravitreal Injection for Ranibizumab on Diabetic Macular Edema[J]. Sichuan Traditional Chinese Medicine, 2022, 40(2): 130-133.
[15]	LOIS N, CAMPBELL C, WAUGH N, et al. Diabetic macular edema and diode subthreshold micropulse laser: a randomized double-masked noninferiority clinical trial[J]. Ophthalmology, 2023, 130(1): 14-27. doi: 10.1016/j.ophtha.2022.08.012
[16]	何燕珊, 王秋红. 白术及其复方治疗糖尿病的药理研究及临床应用研究进展[J]. 广东药科大学学报, 2020, 36(1): 155-158, 封3. HE Y S, WANG Q H. Progress in pharmacological research and clinical application of Atractylodes Macrocephala and its compound in the treatment of diabetes mellitus[J]. Journal of Guangdong Pharmaceutical University, 2020, 36(1): 155-158, 封3.
[17]	曹铭晨, 于振英, 辛兆洋, 等. 基于网络药理学的五苓散多成分-多靶点-多通路作用机制研究[J]. 山东科学, 2020(1): 51-60. CAO M C, YU Z Y, XIN Z Y, et al. Multicomponent-multitarget-multichannel mechanism of Wulingsan based on network pharmacology[J]. Shandong Science, 2020(1): 51-60.
[18]	曾志成, 彭俊, 蒋鹏飞, 等. 益气养阴活血利水复方联合玻璃体腔注射康柏西普治疗糖尿病性黄斑水肿疗效观察[J]. 中国中西医结合杂志, 2019, 39(3): 270-274. ZENG Z C, PENG J, JIANG P F, et al. Observation on the curative effect of Yiqi Yangyin Huoxue Lishui Compound combined with intravitreal injection of Conbercept in the treatment of diabetic macular edema[J]. Chinese Journal of Integrative Medicine, 2019, 39(3): 270-274.
[19]	裴国超, 陈志强, 马赟, 等. 黄芪-生地治疗糖尿病肾病作用机制的网络药理学研究[J]. 中国中西医结合肾病杂志, 2022, 23(9): 786-788, 后插3. PEI G C, CHEN Z Q, MA Y, et al. Network pharmacological study on the mechanism of Astragalus-Shengdi treatment of diabetic nephropathy[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2022, 23(9): 786-788, 后插3.
[20]	孙慧悦, 赵爱霞, 刘会荣, 等. 益气养阴活血汤联合康柏西普治疗DME及对血清VEGF的影响[J]. 国际眼科杂志, 2021, 21(4): 684-688. SUN H Y, ZHAO A X, LIU H R, et al. Effect of Yiqi Yangyin Huoxue Decoction combined with Conbercept on DME and its influence on TCM syndromes and serum VEGF expression[J]. International Eye Science, 2021, 21(4): 684-688.
[21]	朱琴, 戴虹. 房水中细胞因子与玻璃体腔注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿预后的相关性分析[J]. 临床眼科杂志, 2023, 31(5): 409-413. ZHU Q, DAI H. Correlation analysis of cytokines in aqueous humor and intravitreal injection of conbercept for macular edema secondary to central retinal vein occlusion[J]. Journal of Clinical Ophthalmology, 2023, 31(5): 409-413.
[22]	浦利军, 承伟, 顾晖晖, 等. 不同激光光凝治疗时机联合玻璃体注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的有效性及安全性[J]. 中国老年学杂志, 2020, 40(10): 2124-2127. PU L J, CHENG W, GU H H, MOU Z X. Efficacy and safety of different timing of laser photocoagulation combined with vitreous injection of Compacept in the treatment of macular edema secondary to central retinal vein obstruction[J]. Chinese Journal of Gerontology, 2020, 40(10): 2124-2127.